Advice

following a full submission

thiotepa (Tepadina) is not recommended for use within NHS Scotland.

Indication under review: In combination with other chemotherapy medicinal products:
1) with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;
2) when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Two uncontrolled, non-randomised studies including patients with advanced non-Hodgkin’s lymphoma or Hodgkin’s disease have reported data for non-relapse mortality and overall survival.

The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC. 

Download detailed advice127KB (PDF)

Download

Medicine details

Medicine name:
thiotepa (Tepadina)
SMC ID:
790/12
Indication:
In combination with other chemotherapy medicinal products (1): with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; (2): when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Pharmaceutical company
Adienne
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Not recommended
Date advice published:
09 July 2012